

21 . Influenza Virus Research Center

- 1) Wada, T., Morishima, T., Okumura, A., Tashiro, M., Hosoya, M., Shiomi, M., Okuno, Y.: Differences in clinical manifestations of influenza-associated encephalopathy by age. *Microbiol. Immunol.* 53: 83-88, 2009
- 2) Thongratsaku, S., Songserm, T., Poolkhet, C., Kondo, S., Yagi, H., Hiramatsu, H., Tashiro, M., Okada, H., Kato, K., Suzuki, Y.: Determination of N-linked sialyl-sugar chains in the lungs of domestic cats and dogs in Thailand susceptible to the highly pathogenic avian influenza virus (H5N1). *Open Glycoscience* , 2:28-36, 2009.
- 3) Tashiro, M., McKimm-Breschkin, J., Saito, T., Klimov, A., Macken, C., Zambon, M., Hayden, F.: Surveillance for neuraminidase inhibitor-resistant influenza viruses in Japan, 1996-2007. *Antiviral Therapy* 14: 751-761, 2009 WHO/OIE/FAO H5N1 Evolution
- 4) Working Group; Brown, I. H., Capua, I., Cattoli, G., Chen, H., Cox, N., Davis, T., Donis, R. O., Fouchier, R. A. M., Garten, R., Guan, Y., Kawaoka, Y., Mackenzie, J., McCauley, J., Mumford, E., Olsen, C., Perdue, M., Russell, C. A., Smith, C., Smith, D., Smith, G. J. D., Shu, Y., Tashiro, M., Vijaykrishna, D., Webster, R.: Continuing progress towards a unified nomenclature for the highly pathogenic H5N1 avian influenza viruses: divergence of clade 2.2 viruses. *J. Influenza. Resp. Viral Infect.* 3: 59-62, 2009.
- 5) Sriwilaijaroen, N., Wilairat, P., Hiramatsu, H., Takahashi, T., Suzuki, T., Ito, M., Ito, Y., Tashiro, M., Suzuki, Y.: Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. *Virology Journal.* 6:124, 2009
- 6) Bertozzi, S., Kelso, A., Tashiro, M., Savy, V., Farrar, J., Osterholm, M., Jameel, S., Muller, C.P.: Pandemic flu: from front lines. *Nature* 461; 20-21, 2009
- 7) Matsuzaki Y, Takashita E, Okamoto M, Mizuta K, Itagaki T, Katsushima F, Katsushima Y, Nagai Y, and Nishimura H. Evaluation of a new rapid antigen test using immunochromatography for detection of human metapneumovirus in comparison with real-time PCR assay. *J Clin Microbiol.* 47, 2981-2984 (2009)
- 8) Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo S, Mizuta K, Itagaki T, Nishimura H, and Matsuzaki Y. Development and evaluation of a whole virus-based enzyme-linked immunosorbent assay for the detection of human metapneumovirus antibodies in human sera. *J Virol Methods.* 164, 24-29 (2010)
- 9) Muraki Y, Furukawa T, Kohno Y, Matsuzaki Y, Takashita E, Sugawara K, and Hongo S. Influenza C virus NS1 protein up-regulates the splicing of viral mRNAs. *J Virol.* 84, 1957-1966 (2010)
- 10) Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh K, Sugawara K, Takashita E, Itagaki T, Katsushima Y, Ujike M, Obuchi M, Odagiri T, and Tashiro M. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. *Virol J.* 7, 53 (2010)
- 11) Ujike M, Shimabukuro K, Mochizuki K, Obuchi M, Kageyama T, Shirakura M, Kishida N, Yamashita K, Horikawa H, Kato Y, Fujita N, Tashiro M, Odagiri T; Working Group for Influenza Virus Surveillance in Japan. Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. *Emerg Infect Dis.* 16:926-935 (2010)
- 12) .Ikeno D., Kimachi K., Kudo Y., Goto S., Itamura S., Odagiri T., Tashiro M., Kino Y. A prime-boost vaccination of mice with heterologous H5N1 strains. *Vaccine* 27, 3121-3125 (2009)
- 13) Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, Takagi H, Odagiri T, Sata T, Tashiro M, Kobayashi K Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. *J Infect Dis.* 199(11):1629-37, 2009 .
- 14) Kawakami C, Obuchi M, Saikusa M, Noguchi Y, Ujike

- M, Odagiri T, Iwata M, Toyozawa T, Tashiro M. Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season. Jpn J Infect Dis. 62(1):83-6, 2009
- 15) Ichinohe T, Aina A, Nakamura T, Akiyama Y, Maeyama JI, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura SI, Chiba J, Kurata T, Sata T, Hasegawa H. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. J Med Virol. 2010 Jan;82(1):128-37.
- 16) Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, Grohmann G, Hay A, Kelso A, Klimov A, Odagiri T, Smith D, Russell C, Tashiro M, Webby R, Wood J, Ye Z, Zhang W; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2009-2010. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine. 2010 Feb 3;28(5):1156-67. Epub 2009 Dec 9.
- 17) Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K, Tochiwara S, Itamura S, Odagiri T, Tashiro M, Okada K, Miyazaki C, Ueda K. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol. 2010 Feb;54(2):81-8.
- 18) Takahashi H, Kitagawa Y, Maeda-Satoh M, Hasegawa H, Sawa H, Sata T. Monoclonal Antibody and siRNAs for Topoisomerase I Suppress Telomerase Activity. Hybridoma (Larchmt). 2009 Feb;28(1):63-5.
- 19) Hasegawa H*, Ichinohe T, Aina A, Tamura S, Kurata T. Development of an inactivated mucosal vaccine for H5N1 influenza virus. Therapeutic and Clinical Risk Management 2009 Feb;5(1):125-32.
- 20) Ishii K, Hasegawa H, Nagata N, Ami Y, Fukushi S, Taguchi F, Tsunetsugu-Yokota Y. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model. Microbiol Immunol. 2009 Feb;53(2):75-82.
- 21) Kataoka M, Yamamoto A, Ochiai M, Harashima A, Nagata N, Hasegawa H, Kurata T, Horiuchi Y. Comparison of acellular pertussis-based combination vaccines by Japanese control tests for toxicities and laboratory models for local reaction Vaccine 2009 27,1881-1888
- 22) Iizuka I, Saijo M, Shiota T, Ami Y, Suzuki Y, Nagata N, Hasegawa H, Sakai K, Fukushi S, Mizutani T, Ogata M, Nakauchi M, Kurane I, Mizuguchi M, Morikawa S. Loop-mediated isothermal amplification-based diagnostic assay for monkeypox virus infections. J Med Virol. 2009 Jun;81(6):1102-8.
- 23) Hayasaka D, Nagata N, Fujii Y, Hasegawa H, Sata T, Suzuki R, Gould A E, Takashima I, Koike A Mortality following peripheral infection with Tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress response Virology 2009 Jul 20;390(1):139-50. Epub 2009 May 24.
- 24) Saijo M, Ami Y, Suzuki Y, Nagata N, Iwata N, Hasegawa H, Iizuka I, Shiota T, Sakai K, Ogata M, Fukushi S, Mizutani T, Sata T, Kurata T, Kurane I, Morikawa S. Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in nonhuman primates J Gen Virol 2009 Sep;90(Pt 9):2266-71. Epub 2009 May 27.
- 25) Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, Masumi A, Ami Y, Hasegawa H, Hall W. W, Tsujimoto H, Hamaguchi I, Yamaguchi K Identification of Cancer Stem Cells in a Tax-transgenic (Tax-Tg) Mouse Model of Adult T- Cell Leukemia / lymphoma (ATL). Blood 2009 Sep 24;114(13):2709-20. Epub 2009 Jul 7.
- 26) Tobiume M, Sato Y, Katano H, Nakajima N, Tanaka K,

Noguchi A, Inoue S, Hasegawa H, Iwasa Y, Tanaka J, Hayashi H, Yoshida S, Kurane I, Sata T. Rabies virus dissemination in neural tissues of autopsy cases due to rabies imported into Japan from the Philippines: immunohistochemistry. *Pathol Int.* 2009 Aug;59(8):555-66.

- 27) Takahashi H, Ohtaki N, Maeda-Sato M, Tanaka M, Tanaka K, Sawa H, Ishikawa T, Takamizawa A, Takasaki T, Hasegawa H, Sata T, Hall WW, Kurata T, Kojima A. Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus. *Microbes Infect.* 2009 Nov;11(13):1019-28. Epub 2009 Aug 7.
- 28) Kawaguchi A, Orba Y, Kimura T, Iha H, Ogata M, Tsuji T, Ainai A, Sata T, Okamoto T, Hall W.W, Sawa H, Hasegawa H Inhibition of the SDF-1 α -CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. *Blood* 2009 Oct 1;114(14):2961-8. Epub 2009 Aug 5.
- 29) Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. *Vaccine.* 2009 Oct 23;27(45):6276-9.
- 30) Kitagawa Y, Maeda-Sato M, Tanaka K, Tobiume M, Sawa H, Hasegawa H, Kojima A, Hall WW, Kurata T, Sata T, Takahashi H. Covalent bonded Gag multimers in human immunodeficiency virus type-1 particles. *Microbiol Immunol.* 2009 Nov;53(11):609-20.
- 31) Hayasaka D, Nagata N, Hasegawa H, Sata T, Takashima I, Koike S. Early Mortality Following Intracerebral Infection with Tick-Borne Encephalitis Virus Oshima Strain in a Mouse Model. *J Vet Med Sci.* 2009 Dec 9.
- 32) Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. *J Med Virol.* 2010 Jan;82(1):128-37.